GlassScriptPhysician profile
Harjus Singh Birk
NPI 1275064396
$2,472.42
in general payments reported to CMS, 2019-2025
29 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.41 · 2020: $109 · 2022: $22.97 · 2023: $185 · 2024: $851 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,275 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,274.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $386.00 | 2023-2025 | |
| Ucb, INC. | $367.21 | 2023-2025 | Nayzilam, Briviact, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $267.22 | 2023-2025 | Ultomiris, Soliris |
| Abbvie INC. | $187.44 | 2023-2025 | Ubrelvy, Botox |
| Sk Life Science, INC. | $176.70 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.60 | 2023-2025 | Hyqvia |
| Neurocrine Biosciences, INC. | $109.87 | 2019-2025 | |
| Genentech USA, INC. | $93.24 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $88.24 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $64.52 | 2025 | Ajovy, Austedo Xr |
| Amgen INC. | $57.16 | 2024-2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $55.78 | 2024-2025 | Andexxa, Wainua |
| Acadia Pharmaceuticals INC | $47.83 | 2025 | Nuplazid |
| Becton, Dickinson and Company | $45.00 | 2024 | Bd Introsyte |
| Biogen, INC. | $44.05 | 2023-2025 | Skyclarys, Vumerity, Tysabri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36.58 | 2025 | Tremfya |
| Argenx US, INC. | $29.34 | 2025 | Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $29.19 | 2020 | |
| Grifols USA, LLC | $25.01 | 2024 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $24.89 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $22.97 | 2022 | |
| Merz Pharmaceuticals, LLC | $22.29 | 2025 | Xeomin |
| Vanda Pharmaceuticals INC. | $21.76 | 2024 | Ponvory |
| Neurelis, INC. | $20.02 | 2024 | Valtoco |
| Eisai INC. | $18.79 | 2024 | |
| Axsome Therapeutics, INC. | $15.34 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $14.85 | 2020 | |
| Lilly USA, LLC | $14.06 | 2025 | Kisunla, Amyvid |
| Adamas Pharmaceuticals, INC. | $13.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harjus Birk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.